Alkermes (ALKS) Stock Forecast, Price Target & Predictions
ALKS Stock Forecast
Alkermes stock forecast is as follows: an average price target of $35.50 (represents a 28.34% upside from ALKS’s last price of $27.66) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
ALKS Price Target
The average price target for Alkermes (ALKS) is $35.50 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $27.00. This represents a potential 28.34% upside from ALKS's last price of $27.66.
ALKS Analyst Ratings
According to 9 Wall Street analysts, Alkermes's rating consensus is 'Buy'. The analyst rating breakdown for ALKS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (55.56%), 4 'Hold' (44.44%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Alkermes Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 10, 2024 | Akash Tewari | Jefferies | $50.00 | $26.73 | 87.06% | 80.77% |
| Apr 09, 2024 | Vamil Divan | Mizuho Securities | $35.00 | $26.73 | 30.94% | 26.54% |
| Apr 09, 2024 | Akash Tewari | Jefferies | $25.00 | $26.95 | -7.24% | -9.62% |
| Mar 18, 2024 | Joel Beatty | Robert W. Baird | $37.00 | $27.53 | 34.40% | 33.77% |
| Dec 06, 2022 | - | J.P. Morgan | $29.00 | $25.00 | 15.98% | 4.84% |
| Apr 28, 2022 | - | Leerink Partners | $27.00 | $30.38 | -11.13% | -2.39% |
| Apr 21, 2022 | - | Leerink Partners | $25.00 | $29.40 | -14.97% | -9.62% |
| Apr 20, 2022 | - | Goldman Sachs | $35.00 | $28.48 | 22.89% | 26.54% |
The latest Alkermes stock forecast, released on Apr 10, 2024 by Akash Tewari from Jefferies, set a price target of $50.00, which represents a 87.06% increase from the stock price at the time of the forecast ($26.73), and a 80.77% increase from ALKS last price ($27.66).
Alkermes Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $36.75 |
| Last Closing Price | $27.66 | $27.66 | $27.66 |
| Upside/Downside | -100.00% | -100.00% | 32.86% |
In the current month, the average price target of Alkermes stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alkermes's last price of $27.66. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 25, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jul 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 15, 2024 | Cowen & Co. | Underperform | Underperform | Hold |
| Jun 17, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 17, 2024 | Cowen & Co. | - | Buy | Initialise |
| Jun 04, 2024 | Jefferies | Buy | Buy | Hold |
| May 23, 2024 | Piper Sandler | Buy | Buy | Hold |
| May 23, 2024 | Jefferies | Underperform | Underperform | Hold |
| May 22, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 02, 2024 | UBS | Buy | Buy | Hold |
Alkermes's last stock rating was published by H.C. Wainwright on Jul 25, 2024. The company gave ALKS a "Neutral" rating, the same as its previous rate.
Alkermes Financial Forecast
Alkermes Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $377.48M | - | $617.40M | $287.60M | $304.67M | $252.36M | $276.22M | $278.55M | $324.46M | $294.14M | $303.72M | $251.43M | $280.00M | $265.01M | $247.53M | $246.22M | $412.73M | $255.24M | $279.87M | $223.10M | $225.15M | $191.78M |
| Avg Forecast | $408.60M | $390.40M | $385.00M | $359.80M | $380.29M | $386.04M | $393.30M | $360.26M | $362.22M | $362.31M | $458.07M | $283.41M | $289.76M | $271.41M | $268.97M | $256.02M | $306.55M | $301.38M | $275.94M | $235.23M | $268.63M | $238.39M | $232.70M | $228.27M | $404.45M | $252.65M | $252.45M | $216.79M | $175.16M | $95.90M |
| High Forecast | $424.09M | $405.20M | $399.60M | $373.44M | $394.71M | $395.41M | $408.21M | $373.91M | $387.95M | $379.77M | $475.43M | $294.16M | $300.75M | $281.70M | $277.32M | $263.96M | $316.06M | $310.74M | $284.50M | $242.53M | $276.96M | $245.79M | $239.92M | $235.36M | $417.00M | $260.49M | $260.29M | $223.52M | $210.19M | $115.08M |
| Low Forecast | $391.67M | $374.22M | $369.05M | $344.89M | $364.53M | $380.28M | $377.00M | $345.33M | $335.98M | $339.26M | $439.09M | $271.67M | $277.76M | $260.16M | $261.41M | $248.82M | $297.93M | $292.92M | $268.19M | $228.62M | $261.08M | $231.69M | $226.16M | $221.86M | $393.08M | $245.55M | $245.36M | $210.70M | $140.12M | $76.72M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | - | 1.35% | 1.01% | 1.05% | 0.93% | 1.03% | 1.09% | 1.06% | 0.98% | 1.10% | 1.07% | 1.04% | 1.11% | 1.06% | 1.08% | 1.02% | 1.01% | 1.11% | 1.03% | 1.29% | 2.00% |
Alkermes's average Quarter revenue forecast for Mar 24 based on 4 analysts is $360.26M, with a low forecast of $345.33M, and a high forecast of $373.91M. ALKS's average Quarter revenue forecast represents a -4.56% decrease compared to the company's last Quarter revenue of $377.48M (Dec 23).
Alkermes EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $54.63M | - | $239.19M | $-33.77M | $-7.75M | $-40.67M | $-12.36M | $-4.38M | $13.00M | $-4.71M | $26.54M | $4.96M | $-19.45M | $24.58M | $-3.30M | $-7.86M | $21.15M | $-30.13M | $-16.95M | $-77.11M | $-35.79M | $-46.06M |
| Avg Forecast | $6.06M | $5.79M | $5.71M | $5.34M | $5.64M | $5.73M | $5.84M | $-184.51M | $5.38M | $5.38M | $6.80M | $-197.34M | $4.30M | $-3.47M | $3.99M | $-211.06M | $4.55M | $4.47M | $4.10M | $33.48M | $3.99M | $3.54M | $3.45M | $-15.33M | $6.00M | $3.75M | $3.75M | $-91.80M | $-25.57M | $-50.68M |
| High Forecast | $6.29M | $6.01M | $5.93M | $5.54M | $5.86M | $5.87M | $6.06M | $-147.61M | $5.76M | $5.64M | $7.06M | $-157.87M | $4.46M | $-2.77M | $4.12M | $-168.85M | $4.69M | $4.61M | $4.22M | $40.18M | $4.11M | $3.65M | $3.56M | $-12.26M | $6.19M | $3.87M | $3.86M | $-73.44M | $-20.45M | $-40.54M |
| Low Forecast | $5.81M | $5.55M | $5.48M | $5.12M | $5.41M | $5.64M | $5.60M | $-221.42M | $4.99M | $5.04M | $6.52M | $-236.81M | $4.12M | $-4.16M | $3.88M | $-253.27M | $4.42M | $4.35M | $3.98M | $26.78M | $3.87M | $3.44M | $3.36M | $-18.39M | $5.83M | $3.64M | $3.64M | $-110.16M | $-30.68M | $-60.82M |
| Surprise % | - | - | - | - | - | - | - | - | 10.16% | - | 35.18% | 0.17% | -1.80% | 11.73% | -3.10% | 0.02% | 2.86% | -1.05% | 6.48% | 0.15% | -4.88% | 6.95% | -0.95% | 0.51% | 3.52% | -8.04% | -4.52% | 0.84% | 1.40% | 0.91% |
4 analysts predict ALKS's average Quarter EBITDA for Mar 24 to be $-184.51M, with a high of $-147.61M and a low of $-221.42M. This is -437.74% lower than Alkermes's previous annual EBITDA (Dec 23) of $54.63M.
Alkermes Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $160.55M | - | $237.06M | $-41.84M | $-28.25M | $-63.97M | $-30.14M | $-35.90M | $873.00K | $-28.99M | $2.36M | $-22.42M | $-42.64M | $-134.00K | $-29.43M | $-38.65M | $-5.35M | $-52.88M | $-41.99M | $-96.40M | $-62.51M | $-68.88M |
| Avg Forecast | $126.52M | $113.41M | $112.28M | $95.18M | $129.50M | $125.47M | $120.37M | $-282.49M | $76.50M | $67.71M | $62.78M | $-302.12M | $7.16M | $-21.35M | $1.14M | $-323.13M | $12.70M | $9.94M | $18.79M | $-151.32M | $10.55M | $317.85K | $1.01M | $-75.38M | $99.07M | $-32.74M | $-17.25M | $-114.76M | $-44.64M | $-75.79M |
| High Forecast | $132.76M | $119.00M | $117.81M | $99.87M | $135.88M | $140.96M | $126.31M | $-225.99M | $99.78M | $77.16M | $65.88M | $-241.70M | $7.51M | $-17.08M | $1.18M | $-258.50M | $13.22M | $10.34M | $19.55M | $-121.06M | $10.97M | $330.67K | $1.05M | $-60.30M | $103.07M | $-31.55M | $-16.62M | $-91.81M | $-35.71M | $-60.63M |
| Low Forecast | $119.71M | $107.31M | $106.23M | $90.05M | $122.53M | $109.98M | $113.89M | $-338.98M | $56.54M | $48.81M | $59.40M | $-362.55M | $6.77M | $-25.63M | $1.09M | $-387.75M | $12.24M | $9.58M | $18.10M | $-181.59M | $10.16M | $306.24K | $974.55K | $-90.45M | $95.46M | $-34.06M | $-17.94M | $-137.71M | $-53.57M | $-90.95M |
| Surprise % | - | - | - | - | - | - | - | - | 2.10% | - | 3.78% | 0.14% | -3.95% | 3.00% | -26.54% | 0.11% | 0.07% | -2.92% | 0.13% | 0.15% | -4.04% | -0.42% | -29.10% | 0.51% | -0.05% | 1.61% | 2.43% | 0.84% | 1.40% | 0.91% |
Alkermes's average Quarter net income forecast for Mar 24 is $-282.49M, with a range of $-338.98M to $-225.99M. ALKS's average Quarter net income forecast represents a -275.95% decrease compared to the company's last Quarter net income of $160.55M (Dec 23).
Alkermes SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $169.79M | - | $205.26M | $174.48M | $157.54M | $152.78M | $150.38M | $145.05M | $160.41M | $136.21M | $139.19M | $125.17M | $145.78M | $127.65M | $132.03M | $133.37M | $154.45M | $148.70M | $155.07M | $141.22M | $118.15M | $102.10M |
| Avg Forecast | $201.69M | $192.71M | $190.04M | $177.60M | $187.72M | $190.56M | $194.14M | $177.83M | $178.80M | $178.84M | $226.11M | $139.90M | $143.03M | $100.34M | $132.77M | $126.37M | $151.32M | $148.77M | $136.21M | $116.11M | $132.60M | $117.67M | $114.87M | $112.68M | $199.64M | $124.71M | $124.61M | $168.12M | $84.39M | $47.34M |
| High Forecast | $209.34M | $200.01M | $197.25M | $184.34M | $194.84M | $195.18M | $201.50M | $184.57M | $191.50M | $187.46M | $234.68M | $145.20M | $148.45M | $120.41M | $136.89M | $130.30M | $156.01M | $153.39M | $140.44M | $119.72M | $136.71M | $121.32M | $118.43M | $116.18M | $205.84M | $128.58M | $128.48M | $201.74M | $101.27M | $56.81M |
| Low Forecast | $193.33M | $184.72M | $182.17M | $170.24M | $179.94M | $187.71M | $186.09M | $170.46M | $165.84M | $167.47M | $216.74M | $134.10M | $137.11M | $80.27M | $129.04M | $122.82M | $147.07M | $144.59M | $132.38M | $112.85M | $128.87M | $114.37M | $111.64M | $109.51M | $194.03M | $121.21M | $121.11M | $134.50M | $67.51M | $37.87M |
| Surprise % | - | - | - | - | - | - | - | - | 0.95% | - | 0.91% | 1.25% | 1.10% | 1.52% | 1.13% | 1.15% | 1.06% | 0.92% | 1.02% | 1.08% | 1.10% | 1.08% | 1.15% | 1.18% | 0.77% | 1.19% | 1.24% | 0.84% | 1.40% | 2.16% |
Alkermes's average Quarter SG&A projection for Mar 24 is $177.83M, based on 4 Wall Street analysts, with a range of $170.46M to $184.57M. The forecast indicates a 4.74% rise compared to ALKS last annual SG&A of $169.79M (Dec 23).
Alkermes EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 11 |
| EPS | - | - | - | - | - | - | - | - | $0.96 | - | $1.43 | $-0.25 | $-0.17 | $-0.39 | $-0.18 | $-0.22 | $0.01 | $-0.18 | $0.01 | $-0.14 | $-0.27 | $-0.00 | $-0.19 | $-0.24 | $-0.03 | $-0.34 | $-0.27 | $-0.62 | $-0.40 | $-0.45 |
| Avg Forecast | $0.74 | $0.66 | $0.66 | $0.56 | $0.76 | $0.73 | $0.70 | $0.58 | $0.45 | $0.40 | $0.37 | - | $0.04 | $0.03 | $0.01 | $0.02 | $0.07 | $0.06 | $0.11 | $-0.01 | $0.06 | - | $0.01 | $-0.04 | $0.58 | $-0.19 | $-0.10 | $-0.19 | $-0.05 | $-0.10 |
| High Forecast | $0.78 | $0.70 | $0.69 | $0.58 | $0.79 | $0.82 | $0.74 | $0.61 | $0.58 | $0.45 | $0.39 | - | $0.04 | $0.03 | $0.01 | $0.02 | $0.08 | $0.06 | $0.11 | $-0.01 | $0.06 | - | $0.01 | $-0.04 | $0.60 | $-0.18 | $-0.10 | $-0.18 | $-0.04 | $-0.08 |
| Low Forecast | $0.70 | $0.63 | $0.62 | $0.53 | $0.72 | $0.64 | $0.67 | $0.55 | $0.33 | $0.29 | $0.35 | - | $0.04 | $0.03 | $0.01 | $0.02 | $0.07 | $0.06 | $0.11 | $-0.01 | $0.06 | - | $0.01 | $-0.05 | $0.56 | $-0.20 | $-0.10 | $-0.20 | $-0.06 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | - | 2.15% | - | 3.89% | -55.99% | -4.06% | -14.09% | -27.11% | -9.47% | 0.07% | -3.10% | 0.09% | 10.04% | -4.38% | -0.43% | -32.12% | 5.53% | -0.06% | 1.78% | 2.68% | 3.28% | 8.00% | 4.50% |
According to 4 Wall Street analysts, Alkermes's projected average Quarter EPS for Mar 24 is $0.58, with a low estimate of $0.55 and a high estimate of $0.61. This represents a -39.30% decrease compared to ALKS previous annual EPS of $0.96 (Dec 23).
Alkermes Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| DVAX | Dynavax | $11.17 | $24.50 | 119.34% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| EOLS | Evolus | $17.49 | $22.50 | 28.64% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
ALKS Forecast FAQ
Is Alkermes a good buy?
Yes, according to 9 Wall Street analysts, Alkermes (ALKS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 55.56% of ALKS's total ratings.
What is ALKS's price target?
Alkermes (ALKS) average price target is $35.5 with a range of $27 to $50, implying a 28.34% from its last price of $27.66. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alkermes stock go up soon?
According to Wall Street analysts' prediction for ALKS stock, the company can go up by 28.34% (from the last price of $27.66 to the average price target of $35.5), up by 80.77% based on the highest stock price target, and down by -2.39% based on the lowest stock price target.
Can Alkermes stock reach $40?
ALKS's highest twelve months analyst stock price target of $50 supports the claim that Alkermes can reach $40 in the near future.
What are Alkermes's analysts' financial forecasts?
Alkermes's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.52B (high $1.57B, low $1.47B), average EBITDA is $-167M (high $-130M, low $-205M), average net income is $92.85M (high $177.16M, low $7.41M), average SG&A $750.25M (high $776.09M, low $724.21M), and average EPS is $2.78 (high $2.97, low $2.58). ALKS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.54B (high $1.6B, low $1.48B), average EBITDA is $22.91M (high $23.78M, low $21.96M), average net income is $447.39M (high $469.44M, low $423.29M), average SG&A $762.05M (high $790.94M, low $730.47M), and average EPS is $2.62 (high $2.75, low $2.48).
Did the ALKS's actual financial results beat the analysts' financial forecasts?
Based on Alkermes's last annual report (Dec 2022), the company's revenue was $1.11B, beating the average analysts forecast of $1.09B by 2.36%. Apple's EBITDA was $-96.151M, missing the average prediction of $-206M by -53.38%. The company's net income was $-158M, missing the average estimation of $-336M by -52.92%. Apple's SG&A was $605.75M, beating the average forecast of $502.52M by 20.54%. Lastly, the company's EPS was $-0.97, missing the average prediction of $0.0994 by -1075.61%. In terms of the last quarterly report (Dec 2023), Alkermes's revenue was $377.48M, beating the average analysts' forecast of $362.22M by 4.21%. The company's EBITDA was $54.63M, beating the average prediction of $5.38M by 916.20%. Alkermes's net income was $160.55M, beating the average estimation of $76.5M by 109.87%. The company's SG&A was $169.79M, missing the average forecast of $178.8M by -5.04%. Lastly, the company's EPS was $0.96, beating the average prediction of $0.447 by 114.56%